KBL MERGER CORP/SH (NASDAQ:KBLM) and Global Cord Blood (NYSE:CO) are both small-cap unclassified companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.
Global Cord Blood pays an annual dividend of $0.08 per share and has a dividend yield of 1.3%. KBL MERGER CORP/SH does not pay a dividend.
KBL MERGER CORP/SH has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.
This is a summary of current recommendations and price targets for KBL MERGER CORP/SH and Global Cord Blood, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|KBL MERGER CORP/SH||0||0||0||0||N/A|
|Global Cord Blood||0||0||0||0||N/A|
Insider and Institutional Ownership
57.9% of KBL MERGER CORP/SH shares are owned by institutional investors. Comparatively, 16.0% of Global Cord Blood shares are owned by institutional investors. 21.9% of KBL MERGER CORP/SH shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares KBL MERGER CORP/SH and Global Cord Blood’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|KBL MERGER CORP/SH||N/A||N/A||$120,000.00||N/A||N/A|
|Global Cord Blood||$149.34 million||4.90||$37.79 million||N/A||N/A|
Global Cord Blood has higher revenue and earnings than KBL MERGER CORP/SH.
This table compares KBL MERGER CORP/SH and Global Cord Blood’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|KBL MERGER CORP/SH||N/A||15.15%||0.64%|
|Global Cord Blood||24.77%||7.53%||4.00%|
Global Cord Blood beats KBL MERGER CORP/SH on 6 of the 9 factors compared between the two stocks.
About KBL MERGER CORP/SH
KBL Merger Corp. IV is a principle investment firm founded in 2016 and is based in Newark, Delaware.
About Global Cord Blood
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2018, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).
Receive News & Ratings for KBL MERGER CORP/SH Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KBL MERGER CORP/SH and related companies with MarketBeat.com's FREE daily email newsletter.